Company intelligence / Profile preview
Acella Pharmaceuticals
- Ownership
- Private
- Employees
- ~82
- Development stage
- Other
Overview
Acella Pharmaceuticals markets a broad portfolio of affordable generic and specialty pharmaceutical products in the U.S., with commercialized therapies for hypothyroidism and myasthenia gravis among others. The company focuses on quality generics and value-added formulations across multiple therapeutic areas.
- Therapeutic areas
- NeurologyMetabolic DisordersPulmonologyInfectious DiseasesDermatologyHematologyEndocrinologyGastroenterologyRheumatologyWomen's Health
- Modalities
- Small moleculeHormoneProtein
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Acella Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acella Pharmaceuticals.